Home| About us| My LA: login/register| For authors| For reviewers| Submit a paper
(close)

(Ctrl-click to select multiple journals)


How should we address you?

Your email address


 Yes, sign up now
 Sign up for general news too

Privacy Statement
 
 
 

Perspectives in Medicinal Chemistry

Synopsis: An open access, peer reviewed electronic journal that covers drug design in the form of commentaries and reviews which do not require disclosure of proprietary information.


Indexing: 4 major databases. Pubmed indexing for NIH-funded research.

Processing time: Decision in 2 weeks for 90% of papers.

Visibility: Most popular article read 1100+ times.

View factor
for journal
32133


About this journal

Aims:

Perspectives in Medicinal Chemistry (PMC) is an exciting peer-reviewed open access on-line journal. It was developed to help medicinal chemists keep apace with the expanding volume of information published in their field. Rather than providing exhaustive reviews of published work, PMC calls upon leading researchers to succinctly summarize observations from numerous original publications as hybrid review-commentaries. These articles are published continually on the website and are often commissioned by the Editor in Chief. While the submission of completed manuscripts is acceptable, we encourage proposals for future articles sent to the Managing Editor. These proposals should provide a rationale and brief outline (<250 words) for the article.

Scope:

Articles published in PMC are succinct and carefully-illustrated works intending to provide a thoughtful overview of a significant research area in medicinal chemistry. Importantly, these articles provide a representative but not exhaustive overview of recent advances in a particular research field. Articles in PMC provide insight on the implications of the new developments and provide an opportunity for authors to discuss their ideas of 'the road ahead' in their research areas. These articles are carefully peer-reviewed to ensure a balanced representation of the literature.

Perspectives in Medicinal Chemistry will publish articles that combine aspects of commentaries and reviews, allowing medicinal chemists to discuss drug design without the necessity of revealing proprietary information. Authors are encouraged to submit review-type manuscripts which go beyond conventional reviews by incorporating a sense of perspective to enhance articles' value to readers and to allow authors to demonstrate and share their perspectives in drug discovery.

Editorial standards and procedures:

Submissions, excluding editorials, letters to the editor and dedications, will be peer reviewed by two reviewers.  Reviewers are required to provide fair, balanced and constructive reports.  

Under our Fairness in Peer Review Policy authors may appeal against reviewers' recommendations which are ill-founded, unobjective or unfair.  Appeals are considered by the Editor in Chief or Associate Editor.

Papers are not sent to peer reviewers following submission of a revised manuscript. Editorial decisions on re-submitted papers are based on the author's response to the initial peer review report.

Indexing:

This journal is indexed by the following services:

  • Embase
  • Google Scholar
  • CAS
  • DOAJ

SPARC Europe Seal award winner:

This journal has been awarded a SPARC Europe Seal. The Seal is an initiative of SPARC Europe (Scholarly Publishing and Academic Resources Coalition) and the Directory of Open Access Journals (DOAJ) which is awarded to journals applying a Creative Commons CC-BY copyright license and that make journal metadata accessible to DOAJ.  

Amongst other important services DOAJ makes metadata OAI-compliant.  This in turn enhances the visibility of papers and allows OAI-harvesters to include the details of journal articles in their services. We encourage readers to make use of this valuable resource.  The DOAJ search page is available here.

National Institutes of Health Public Access Policy compliant:

As of April 7 2008, the US NIH Public Access Policy requires that all peer reviewed articles resulting from research carried out with NIH funding be deposited in the Pubmed Central archive.

If you are an NIH employee or grantee Libertas Academica will ensure that you comply with the policy by depositing your paper at Pubmed Central on your behalf. 

ISSN: 1177-3910


Bookmark journal

FACEBOOK
YAHOO! BUZZ
DIGG
LINKEDIN
Add to Mixx! MIXX
PERMALINK


 
 
 


The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy

Authors: Xinjie Lu, Dong Lu, Mike Scully and Vijay Kakkar
Publication Date: 10 Apr 2008
Perspectives in Medicinal Chemistry 2008:2 57-73

Xinjie Lu1, Dong Lu2, Mike Scully1 and Vijay Kakkar1

1Thrombosis Research Institute, Manresa Road, London, SW3 6LR U.K. 2The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, U.K.

Abstract

Integrins have been reported to mediate cell survival, proliferation, differentiation, and migration programs. For this reason, the past few years have seen an increased interest in the implications of integrin receptors in cancer biology and tumor cell aggression. This review considers the potential role of integrins in cancer and also addresses why integrins are present attractive targets for drug design. It discusses of the several properties of the integrin-based chemotherapeutic agents currently under consideration clinically and provides an insight into cancer drug development using integrin as a target.

Categories: Pharmacology


Post comment




No comments yet...Be the first to comment.

Document tools

Download PDF
(500.06 KB)
Request Reprints

Bookmark this article

LINKEDIN FACEBOOK

Add to Mixx! MIXX YAHOO! BUZZ

PERMALINK DIGG


Sign up for free journal updates

How should we address you?
Your email address
 Yes, sign up now


Recently published in this journal

Aminoglycosides: Molecular Insights on the Recognition of RNA and Aminoglycoside Mimics
- 28/Apr/2009

Perspectives on Using Physcomitrella  Patens as an Alternative Production Platform for Thapsigargin and Other Terpenoid Drug Candidates
- 04/Mar/2009

Bioactive and Structural Metabolites of Pseudomonas and Burkholderia Species Causal Agents of Cultivated Mushrooms Diseases
- 09/May/2008

The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy
- 10/Apr/2008

Drug Targeting of α-Synuclein Oligomerization in Synucleinopathies
- 10/Apr/2008

Lunasin: A Novel Cancer Preventive Seed Peptide
- 25/Mar/2008

Effects of FK506 on Ca2+ Release Channels (Review)
- 18/Mar/2008

Small Family with Key Contacts: Par14 and Par17 Parvulin Proteins, Relatives of Pin1, Now Emerge in Biomedical research
- 07/Mar/2008

Modifications of Antiepileptic Drugs for Improved Tolerability and Efficacy
- 14/Feb/2008

Exploratory Studies on Development of the Chemokine Receptor CXCR4 Antagonists Toward Downsizing
- 10/Feb/2008

The Role of Glucose Metabolism and Glucose-Associated Signalling in Cancer
- 18/Jan/2008

Chemical Chaperone and Inhibitor Discovery: Potential Treatments for Protein Conformational Diseases
- 11/Dec/2007

Derivatives of 5-Aminolevulinic Acid for Photodynamic Therapy
- 11/Dec/2007

The pKa Distribution of Drugs: Application to Drug Discovery
- 17/Sep/2007

FTY720 Story. Its Discovery and the Following Accelerated Development of Sphingosine 1-Phosphate Receptor Agonists as Immunomodulators Based on Reverse Pharmacology
- 06/Sep/2007

Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034
- 26/Jun/2007



Related journals...